Amgen Inc (AMGN) Stock Price & Analysis
Amgen Inc (AMGN) fell 0.34% to USD 344.57 as of June 9, 2026 at 22:36 UTC, according to Nexqual real-time market data.
AMGN last closed at USD 345.73; the session ranged USD 342.62–349.64 on volume of 3,263,316 shares. Market capitalization is $185.96B, with a 52-week range of USD 267.83–391.29 (NMS). Source: Nexqual, June 9, 2026 at 22:36 UTC.
Key Statistics (as of June 9, 2026 at 22:36 UTC)
| Price | USD 344.57 |
|---|---|
| Change | ▼ 0.34% (down) |
| Previous Close | USD 345.73 |
| Open | USD 348.24 |
| Day Range | USD 342.62 – 349.64 |
| 52-Week Range | USD 267.83 – 391.29 |
| Volume | 3,263,316 shares |
| Market Cap | $185.96B |
| Exchange | NMS |
Technical Analysis (AMGN)
Nexqual's technical model rates AMGN "STRONG BUY" based on 5 bullish and 0 bearish signals across 124 daily candles, as of June 9, 2026 at 22:36 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 54.72 (neutral) |
| vs SMA50 | Above (USD 340.45) |
| MACD | 1.34 (positive) |
Analyst Ratings (AMGN)
Wall Street analysts rate AMGN "Buy" based on 30 analysts, with a mean price target of USD 352.23 (range USD 200–427), per Nexqual as of June 9, 2026 at 22:36 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 30 |
| Mean Target | USD 352.23 |
| High Target | USD 427 |
| Low Target | USD 200 |
| Buy / Hold / Sell | 14 / 18 / 3 |
Earnings (AMGN)
| Next Earnings Date | 2026-08-04 |
|---|---|
| EPS Estimate | USD 5.59 |
| Revenue Estimate | $9.42B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 5.15 vs est 4.77 ▲ beat |
| 2025-12-31 | USD 5.29 vs est 4.73 ▲ beat |
| 2025-09-30 | USD 5.64 vs est 5.01 ▲ beat |
| 2025-06-30 | USD 6.02 vs est 5.28 ▲ beat |
Source: Nexqual, June 9, 2026 at 22:36 UTC.
Financials & Fundamentals (AMGN)
| Total Revenue | $37.22B |
|---|---|
| Revenue Growth (YoY) | +5.80% |
| Gross Margin | +71.44% |
| Operating Margin | +33.80% |
| Profit Margin | +20.96% |
| ROE | +101.32% |
| Debt / Equity | 623.75 |
| Current Ratio | 1.26 |
| Total Cash | $12.04B |
| Total Debt | $57.32B |
| Free Cash Flow | $7.44B |
Source: Nexqual, June 9, 2026 at 22:36 UTC.
Financial Health Score (AMGN)
Nexqual rates Amgen Inc's overall financial health "Solid" across five dimensions, as of June 9, 2026 at 22:36 UTC.
| Growth | Solid — Revenue +10% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 71%, operating 34% |
| Balance Sheet | Critical — $12.0B cash vs $57.3B debt |
| Cash Flow | Strong — FCF $7.44B, 20% margin |
| Efficiency | Strong — ROE 101%, ROA 8.3% |
Ownership (AMGN)
| Insider Ownership | +0.22% |
|---|---|
| Institutional Ownership | +85.43% |
| Shares Outstanding | 539.71M |
| Float | 538.23M |
| Short % of Float | +2.28% |
Source: Nexqual, June 9, 2026 at 22:36 UTC.
Leadership (AMGN)
Amgen Inc is led by Robert A. Bradway (age 62), Chairman & CEO, per Nexqual as of June 9, 2026 at 22:36 UTC.
| Chairman & CEO | Robert A. Bradway (age 62) |
|---|---|
| Executive VP & CFO | Peter H. Griffith (age 66) |
| Executive VP & CTO | David M. Reese (age 62) |
| Executive Vice President of Operations | Esteban Santos (age 57) |
| Senior Vice President of Rare Disease, Global Commercial Capabilities & Innovation | Jasper van Grunsven |
Major Backers & Investors (AMGN)
Notable institutional backers of Amgen Inc include Capital Group, Morgan Stanley, Charles Schwab Investment Management, Inc., according to Nexqual as of June 9, 2026 at 22:36 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Capital Group | 5.43% |
| Morgan Stanley | 2.93% |
| Charles Schwab Investment Management, Inc. | 2.37% |
| Invesco | 2.14% |
| Primecap Management Company | 1.64% |
| Charles Schwab | 1.61% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 14.91% |
| BlackRock | 10.02% |
| State Street | 6.85% |
| Geode Capital | 2.86% |
Source: Nexqual, June 9, 2026 at 22:36 UTC.
From Amgen Inc's Latest SEC 10-K Filing (filed 2026-02-13)
Key Strengths & Strategy (as disclosed to the SEC)
- Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide.
- It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI.
- The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies.
- It distributes its products through pharmaceutical wholesale distributors.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| BIIB | Biogen Inc. | USD 199.1 | ▲ 1.92% |
| GILD | Gilead Sciences, Inc. | USD 125.5 | ▼ 2.83% |
| BMY | Bristol-Myers Squibb Company | USD 56.48 | ▼ 1.38% |
| MRK | Merck & Company, Inc. | USD 119.6 | ▼ 0.99% |
| LLY | Eli Lilly and Company | USD 1,144.68 | ▲ 1.17% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 9, 2026 at 22:36 UTC. This page is informational and not investment advice.